share_log

Rockwell Medical Partners With HydroCare to Distribute and Install Its Dry Acid Concentrate Mix System

Rockwell Medical Partners With HydroCare to Distribute and Install Its Dry Acid Concentrate Mix System

rockwell medical與HydroCare合作,分銷和安裝其幹酸濃縮混合系統。
Rockwell Medical ·  12/05 13:00

WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has partnered with HydroCare, a leading provider of state-of-the-art dialysis water treatment systems to healthcare facilities globally, to purchase and install the Company's dry acid concentrate mix system in dialysis water rooms. Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure                                                                                 and Dri-Sate                                                                                 dry acid concentrate powders.                                    

位於密歇根州WIXOm--(商業新聞)-- 羅克威爾醫療公司("公司")(納斯達克:RMTI),是一家開發、製造、商業化和分銷透析產品組合的醫療保健公司,面向全球透析供應商,今天宣佈公司已與HydroCare達成合作,HydroCare是一家領先的醫療機構最高效透析水處理系統提供商,購買並安裝公司的幹酸濃縮混合系統於透析水房。羅克威爾預計,通過HydroCare的新混合器安裝,公司還將獲得與其幹酸透析濃縮液相關的新銷售。羅克威爾醫療的DAMX45幹酸濃縮混合系統獲得510(k)認證,僅用於公司的CitraPure和Dri-Sate幹酸濃縮粉末。

"The dialysis water room is the heartbeat of the dialysis unit, housing the systems that provide highly purified water. It requires regular upkeep to stay clean and toxin-free," says Eric Cirignano, Founder and CEO of HydroCare. "At HydroCare, we focus on providing reliable dialysis water treatment systems that put patient safety first. Our product range includes large RO systems, disposables, and replacement parts. We needed a simple, easy-to-train solution for dry acid mixers, and found that and more with Rockwell Medical's 'ready-to-use' DAMX45 dry acid concentrate mix system."

"透析水房間是透析單元的中樞,容納提供高度純淨水的系統。它需要定期維護以保持清潔和無毒",HydroCare的創始人兼首席執行官Eric Cirignano說道。"在HydroCare,我們專注於提供可靠的透析水處理系統,將患者安全放在第一位。我們的產品範圍包括大型RO系統、一次性用品和更換零件。我們需要一個簡單、易於培訓的幹酸混合器解決方案,Rockwell Medical的'DAMX45幹酸濃縮混合系統'正好符合我們的需求。"

"We are excited to partner with HydroCare to sell and install our dry acid mixers as part of their dialysis water room installations," said                                         Tim Chole, Chief Commercial Officer at Rockwell Medical. "Our mixer is compact, quick and easy to install, and FDA-approved for Rockwell's dry acid products. Using a forced RO water pump to mix the product, our mixer enables a dialysis clinic to mix 100 gallons of acid concentrate on-site in just three minutes. We believe that this partnership with HydroCare offers us another avenue to install Rockwell's mixers into more clinics to benefit more patients."                                    

"我們很高興能與HydroCare合作,賣出並安裝我們的幹酸混合器,作爲他們透析水房安裝的一部分," 羅克威爾醫療的首席商業官tim Chole說。 "我們的混合器體積小,快速且易於安裝,並且獲得FDA批准用於羅克威爾的幹酸產品。使用強制RO水泵混合產品,我們的混合器使透析診所能夠在現場僅用三分鐘混合100加侖的酸濃縮液。我們相信,這與HydroCare的合作爲我們提供了另外一種途徑,將羅克威爾的混合器安裝到更多診所,造福更多的患者。"

About HydroCare

關於HydroCare

HydroCare isn't just meeting the dialysis community's stringent water filtration standards—we're revolutionizing them. Our dialysis water system are engineered to guarantee that patients receive nothing less than the safest, most reliable water for their treatments, every single time. By integrating technologies like reverse osmosis, innovative endotoxin-retentive filters, and cutting-edge pretreatment systems, HydroCare obliterates organic and inorganic contaminants. This is how we redefine the future of dialysis water—pure, compliant, and uncompromising in quality. For more information, visit                                         hydrocare.us.                                    

HydroCare不僅滿足透析社區嚴格的水過濾標準——我們正在徹底革命這些標準。我們的透析水系統旨在確保患者每次接受治療時都能獲得最安全、最可靠的水。通過整合反滲透、創新的內毒素保留過濾器和尖端預處理系統等技術,HydroCare消除了有機和無機污染物。這就是我們如何重新定義透析水的未來——純淨、合規、質量無妥協。有關更多信息,請訪問 hydrocare.us。

About Rockwell Medical

關於Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work                                                                                 in 2023 and 2024 and named                                         Fortune                                         Best Workplaces in Manufacturing & Production                                        TM                                         in 2024, Rockwell Medical is                                                                                    Driven to Deliver Life-Sustaining Dialysis Solutions                                            TM                                            .                                                                                For more information, visit                                         .                                    

Rockwell Medical, Inc.(納斯達克:RMTI)是一家醫療保健公司,開發、製造、商業化和分銷一系列透析產品,服務於全球的透析提供商。Rockwell Medical的使命是爲透析診所及其服務的患者提供最高質量的產品,並提供行業內最佳的客戶服務。Rockwell專注於創新的長期增長策略,以提升其產品、流程和人員,使公司能夠爲醫療保健系統提供卓越的價值,並對透析患者的生活產生積極影響。透析是終末期腎病治療中最常見的形式,通常在獨立的門診透析中心、醫院門診中心、熟練護理設施或患者家中進行。Rockwell Medical的產品對處於脆弱狀態的終末期腎病患者至關重要,公司在提供無與倫比的可靠性和客戶服務方面不遺餘力。被認證爲2023年和2024年的最佳工作場所,並被《財富》雜誌評選爲2024年最佳製造與生產工作場所,Rockwell Medical致力於提供生命維持的透析解決方案。有關更多信息,請訪問。

Forward-Looking Statements

前瞻性聲明

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," "are determined," "are on track," "are resolute in our vision," or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include statements relating to generating new sales and installing the Rockwell Medical mixer into additional dialysis clinics. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

本新聞稿中的某些聲明可能構成《前瞻性聲明》,屬於聯邦證券法的範疇。諸如「可能」、「或許」、「將會」、「應當」、「相信」、「期待」、「預計」、「估計」、「持續」、「可能」、「會」、「發展」、「計劃」、「潛力」、「預測」、「展望」、「充滿信心」、「堅定決心」、「按計劃進行」、「固守我們的願景」或類似表述的詞語,或關於意圖、信念或目前期望的聲明,均屬前瞻性聲明。這些聲明包括與生成新銷售額並將Rockwell Medical混合器安裝到額外透析診所相關的聲明。雖然Rockwell Medical認爲這些前瞻性聲明是合理的,但不應過分依賴任何此類前瞻性聲明,這些聲明是基於我們在本發佈日期可獲得的信息。這些前瞻性聲明基於當前估計和假設,受各種風險和不確定性(包括但不限於Rockwell Medical提交給SEC的各種風險因素)的影響,其中許多超出我們的控制,並可能發生變化。實際結果可能截然不同。風險和不確定性包括但不限於我們在截至2023年12月31日的年度10-k表格「風險因素」部分更全面討論的風險,此描述可能在我們將來向SEC提交的任何未來報告中進行修改或更新。Rockwell Medical明確聲明不承擔更新我們的前瞻性聲明的義務,除非法律要求。

Heather R. Hunter                                        
SVP, Chief Corporate Affairs Officer                                        
(248) 432-1362                                        
IR@RockwellMed.com

希瑟·R·亨特
高級副總裁,首席公司事務官
(248) 432-1362                                        
IR@RockwellMed.com

Source: Rockwell Medical

來源:rockwell medical

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論